Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Hey SPPI, Update your 'NSCLC-Exon-20 Patient Population' Presentation slide please. The slide indicates that there are between 3500 - 7200 advanced NSCLC patients with EGFR and HER2ex20in in the US, or an average of 5350. Just got my hands on the Nature Medicine April 2018 article on pozi, Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer and it indicates in the Discussion that value should be 7000 patients. That's considerable more patients than the Presentation average of 5350.

A Corollary to this is that it's good to know that SPPI is not trying to overstate the # of patients that would be able to use pozi.